Aryl-substituted pyrrolopyrimidines showed potent inhibition of the membrane bound epidermal growth factor receptor tyrosine kinase (EGFR) and angiogenic inhibitors against human vascular endothelial growth factor receptor-2 (VEGFR-2) that represent important targets in cancer therapy [17,18,19,20,21,22,23,24]. Here, KDR is linked to cancer.